NASDAQ: OCS - Oculis Holding AG

Yield per half year: +25.17%
Dividend yield: 0%
Sector: Healthcare

Share chart Oculis Holding AG


About Oculis Holding AG

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye.

more details
The company's lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for keratoconjunctivitis sicca, or dry eye disease; and OCS-05, a novel neuroprotective agent for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland.

IPO date 2023-03-02
ISIN CH1242303498
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета chf
Сайт https://oculis.com
Цена ао 17.76
Change price per day: 0% (18.3)
Change price per week: -1.51% (18.58)
Change price per month: +1.55% (18.02)
Change price per 3 month: -15.24% (21.59)
Change price per half year: +25.17% (14.62)
Change price per year: +52.63% (11.99)
Change price per 3 year: +87.69% (9.75)
Change price per year to date: +7.71% (16.99)

Underestimation

Title Value Grade
P/S 317.87 1
P/BV 9.18 1
P/E 0 0
EV/EBITDA -5.31 0
Total: 2.38

Efficiency

Title Value Grade
ROA, % -73.09 0
ROE, % -102.66 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.0258 10
Total: 9.6

Growth impulse

Title Value Grade
Yield Revenue, % -11.08 0
Yield Ebitda, % 277.99 10
Yield EPS, % 282.88 10
Total: 8



Head Job title Payment Year of birth
Dr. Riad Sherif M.B.A., M.D. CEO & Director N/A 1968 (57 years)
Ms. Sylvia Cheung Chief Financial Officer N/A 1975 (50 years)
Mr. Páll Ragnar Jóhannesson Chief Business Officer N/A 1982 (43 years)
Ms. Rebecca Weil Chief Commercial Officer N/A
Dr. Ramin Tadayoni M.D., Ph.D. Chief Scientific Officer N/A
Ms. Virginia R. Dean Chief Human Resources Officer N/A 1967 (58 years)
Dr. Bastian Dehmel M.D. Chief Development Officer N/A 1971 (54 years)
Dr. Snehal Shah Pharm.D. President of Research & Development N/A
Dr. Sharon Klier M.D., M.P.H. Chief Development Officer

Address: Switzerland, Zug, Bahnhofstrasse 7 - open in Google maps, open in Yandex maps
Website: https://oculis.com